Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors
05 janv. 2022 08h30 HE
|
Lixte Biotechnology Holdings, Inc.
Outside research shows that in models of colorectal, triple-negative breast and pancreatic cancer, LB-100 induces molecular changes that render the cancers more vulnerable to immunotherapy ...
Lixte Biotechnology to Discuss its Collaboration with Leading European Cancer Centers at the Benzinga Global Small Cap Conference on October 28
20 oct. 2021 09h25 HE
|
Lixte Biotechnology Holdings, Inc.
Studies to use genome wide functional genetic techniques to identify effective drug combinations and new drug targets for its lead clinical compound, LB-100 PASADENA, CA, Oct. 20, 2021 (GLOBE...
Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment
13 oct. 2021 09h25 HE
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced entry into a collaboration with the Netherlands Cancer Institute, Amsterdam (NKI) , one of...
Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer
02 juin 2021 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
Extensive preclinical data shows LB-100 increases the effectiveness of chemotherapy in animal modelsDue to the aggressive progression of small cell lung cancer, it is possible that therapeutic benefit...
LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THE APPOINTMENT OF REGINA BROWN TO ITS BOARD OF DIRECTORS
12 mai 2021 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, May 12, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) today announced the appointment of Regina Brown, CPA to its board of directors. She will serve...
Lixte Biotechnology to Present Key Advantages of Novel Cancer Drug Candidate LB-100 at the Sidoti Virtual Microcap Conference on May 20
04 mai 2021 16h30 HE
|
Lixte Biotechnology Holdings, Inc.
Multiple pre-clinical studies indicate that Lixte’s lead clinical drug candidate LB-100 enhances the effectiveness of many standard anticancer treatments EAST SETAUKET, NY, May 04, 2021 (GLOBE...
Lixte Biotechnology to Present Its Novel Product Candidate for Targeted Cancer Therapy at the Benzinga Biotech Small Cap Conference on March 24
17 mars 2021 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
More than 40 preclinical studies have found that Lixte’s lead drug candidate LB-100 increases the anti-tumor activity of chemotherapy, radiotherapy and immunotherapy without increasing toxicity EAST...
Lixte Biotechnology Announces $4.19 Million Registered Direct Offering
01 mars 2021 08h45 HE
|
Lixte Biotechnology Holdings, Inc.
East Setauket, March 01, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in...
Lixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences Conference
24 févr. 2021 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
LB-100 is Currently in Clinical Studies for Four Cancer Targets: Phase 1b/2 for Myelodysplastic (MDS) SyndromesPhase 1b/2 for Advanced Soft Tissue SarcomaPhase 0 (Pharmacodynamics) for Glioblastoma...
Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer
19 janv. 2021 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in...